Swedish Orphan Biovitrum AB (publ) 0MTD.IL Stock
Swedish Orphan Biovitrum AB (publ) Price Chart
Swedish Orphan Biovitrum AB (publ) 0MTD.IL Financial and Trading Overview
| Swedish Orphan Biovitrum AB (publ) stock price | 252.2 SEK |
| Previous Close | 219 SEK |
| Open | 221.4 SEK |
| Bid | 218.6 SEK x 0 |
| Ask | 227.8 SEK x 0 |
| Day's Range | 221.4 - 224.8 SEK |
| 52 Week Range | 199.2 - 273.8 SEK |
| Volume | 3.06K SEK |
| Avg. Volume | 164.6K SEK |
| Market Cap | 67.87B SEK |
| Beta (5Y Monthly) | 0.395402 |
| PE Ratio (TTM) | 21.553211 |
| EPS (TTM) | 9.73 SEK |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0MTD.IL Valuation Measures
| Enterprise Value | 75.77B SEK |
| Trailing P/E | 21.553211 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.5525436 |
| Price/Book (mrq) | 2.3961031 |
| Enterprise Value/Revenue | 3.966 |
| Enterprise Value/EBITDA | 11.208 |
Trading Information
Swedish Orphan Biovitrum AB (publ) Stock Price History
| Beta (5Y Monthly) | 0.395402 |
| 52-Week Change | 7.12% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 273.8 SEK |
| 52 Week Low | 199.2 SEK |
| 50-Day Moving Average | 242.23 SEK |
| 200-Day Moving Average | 228.61 SEK |
0MTD.IL Share Statistics
| Avg. Volume (3 month) | 164.6K SEK |
| Avg. Daily Volume (10-Days) | 117.55K SEK |
| Shares Outstanding | 296.61M |
| Float | 157.73M |
| Short Ratio | N/A |
| % Held by Insiders | 4.00% |
| % Held by Institutions | 70.42% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 16.55% |
| Operating Margin (ttm) | 23.95% |
| Gross Margin | 77.36% |
| EBITDA Margin | 35.39% |
Management Effectiveness
| Return on Assets (ttm) | 5.57% |
| Return on Equity (ttm) | 12.25% |
Income Statement
| Revenue (ttm) | 19.1B SEK |
| Revenue Per Share (ttm) | 64.57 SEK |
| Quarterly Revenue Growth (yoy) | 6.40% |
| Gross Profit (ttm) | 14.38B SEK |
| EBITDA | 6.76B SEK |
| Net Income Avi to Common (ttm) | 3.16B SEK |
| Diluted EPS (ttm) | 10.43 |
| Quarterly Earnings Growth (yoy) | 96.50% |
Balance Sheet
| Total Cash (mrq) | 198M SEK |
| Total Cash Per Share (mrq) | 0.67 SEK |
| Total Debt (mrq) | 9.23B SEK |
| Total Debt/Equity (mrq) | 33.18 SEK |
| Current Ratio (mrq) | 0.7 |
| Book Value Per Share (mrq) | 93.819 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 5B SEK |
| Levered Free Cash Flow (ttm) | -456124992 SEK |
Profile of Swedish Orphan Biovitrum AB (publ)
| Country | United Kingdom |
| State | N/A |
| City | Solna |
| Address | Tomtebodavägen 23A |
| ZIP | 112 76 |
| Phone | 46 86 97 20 00 |
| Website | https://www.sobi.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 1612 |
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to treat paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.
Q&A For Swedish Orphan Biovitrum AB (publ) Stock
What is a current 0MTD.IL stock price?
Swedish Orphan Biovitrum AB (publ) 0MTD.IL stock price today per share is 252.2 SEK.
How to purchase Swedish Orphan Biovitrum AB (publ) stock?
You can buy 0MTD.IL shares on the IOB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Swedish Orphan Biovitrum AB (publ)?
The stock symbol or ticker of Swedish Orphan Biovitrum AB (publ) is 0MTD.IL.
Which industry does the Swedish Orphan Biovitrum AB (publ) company belong to?
The Swedish Orphan Biovitrum AB (publ) industry is Drug Manufacturers-Specialty & Generic.
How many shares does Swedish Orphan Biovitrum AB (publ) have in circulation?
The max supply of Swedish Orphan Biovitrum AB (publ) shares is 361.79M.
What is Swedish Orphan Biovitrum AB (publ) Price to Earnings Ratio (PE Ratio)?
Swedish Orphan Biovitrum AB (publ) PE Ratio is 25.92009500 now.
What was Swedish Orphan Biovitrum AB (publ) earnings per share over the trailing 12 months (TTM)?
Swedish Orphan Biovitrum AB (publ) EPS is 9.73 SEK over the trailing 12 months.
Which sector does the Swedish Orphan Biovitrum AB (publ) company belong to?
The Swedish Orphan Biovitrum AB (publ) sector is Healthcare.